What is the Return on Assets (ROA) of Hepion Pharmaceuticals this year?
The Return on Assets (ROA) of Hepion Pharmaceuticals is -2.7 undefined this year.
Hepion Pharmaceuticals ROA 2024
Hepion Pharmaceuticals ROA
-2.7
Ticker
HEPA
ISIN
US4268971045
WKN
A2PN6W
In 2024, Hepion Pharmaceuticals's return on assets (ROA) was -2.7, a 259.01% increase from the -0.75 ROA in the previous year.
Hepion Pharmaceuticals Aktienanalyse
What does Hepion Pharmaceuticals do?
Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing therapeutics for the treatment of liver diseases. The company was founded in 2013 and is headquartered in Edison, New Jersey. The history of Hepion Pharmaceuticals Inc. began with the discovery of a new approach to treating liver diseases. Researchers found that small molecules targeting specific cells in the liver could have a positive effect on liver function. Hepion used this discovery as a starting point for developing new drugs to treat liver diseases. Hepion Pharmaceuticals Inc.'s business model is based on the development and marketing of innovative therapeutics for a variety of liver diseases, including fatty liver disease, alcoholic liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and liver cancer. Hepion Pharmaceuticals has several divisions, all focused on the development of therapeutics for liver diseases. The primary division is research and development, which focuses on identifying and developing new drugs for the liver. Another important division is clinical development, where the drugs are tested and validated in clinical trials. The third division is marketing, where the therapeutics are marketed and sold. Hepion Pharmaceuticals Inc. currently offers two products. The first product is CRV431, a top-notch inhibitor of cytokine-mediated signaling. It is an orally administered drug specifically developed for the treatment of liver fibrosis. CRV431 aims to inhibit cytokine-mediated signaling responsible for fibrosis formation. The second product is an idiosyncratic database marketed under the name AI-Enabler. It is touted by the company as a groundbreaking tool for more precise medicine and research in support of drug development work. Overall, Hepion Pharmaceuticals Inc. is a promising biopharma company with a clear focus on developing new drugs for the treatment of liver diseases. With its innovative products and expertise in research and development, the company collaborates closely with partners from the scientific, industrial, and governmental sectors. It is hoped that this company will make further pioneering discoveries in the future and contribute to the benefit of human health. Hepion Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Hepion Pharmaceuticals's Return on Assets (ROA)
Hepion Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Hepion Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Hepion Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Hepion Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Hepion Pharmaceuticals stock
What was the ROA of Hepion Pharmaceuticals compared to the previous year?
The ROA of Hepion Pharmaceuticals has increased by 259.01% compared to the previous year.
What consequences do high ROA have for investors of Hepion Pharmaceuticals?
A high ROA is advantageous for investors of Hepion Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Hepion Pharmaceuticals?
A low ROA can be unfavorable for investors of Hepion Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Hepion Pharmaceuticals affect the company?
An increase in ROA of Hepion Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Hepion Pharmaceuticals impact the company?
A reduction in the ROA of Hepion Pharmaceuticals can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Hepion Pharmaceuticals?
Some factors that can influence the ROA of Hepion Pharmaceuticals include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Hepion Pharmaceuticals important for investors?
The ROA of Hepion Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Hepion Pharmaceuticals take to improve ROA?
To improve ROA, Hepion Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Hepion Pharmaceuticals pay?
Over the past 12 months, Hepion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hepion Pharmaceuticals is expected to pay a dividend of 0 USD.
What is the dividend yield of Hepion Pharmaceuticals?
The current dividend yield of Hepion Pharmaceuticals is .
When does Hepion Pharmaceuticals pay dividends?
Hepion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Hepion Pharmaceuticals?
Hepion Pharmaceuticals paid dividends every year for the past 0 years.
What is the dividend of Hepion Pharmaceuticals?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Hepion Pharmaceuticals located?
Hepion Pharmaceuticals is assigned to the 'Health' sector.
Wann musste ich die Aktien von Hepion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Hepion Pharmaceuticals from 9/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/25/2024.
When did Hepion Pharmaceuticals pay the last dividend?
The last dividend was paid out on 9/25/2024.
What was the dividend of Hepion Pharmaceuticals in the year 2023?
In the year 2023, Hepion Pharmaceuticals distributed 0 USD as dividends.
In which currency does Hepion Pharmaceuticals pay out the dividend?
The dividends of Hepion Pharmaceuticals are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Hepion Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Hepion Pharmaceuticals
Our stock analysis for Hepion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hepion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Hepion Pharmaceuticals Revenue
- Hepion Pharmaceuticals Net Income
- Hepion Pharmaceuticals P/E
- Hepion Pharmaceuticals P/S
- Hepion Pharmaceuticals EBIT
- Hepion Pharmaceuticals Dividend
- Hepion Pharmaceuticals Stocks
- Hepion Pharmaceuticals Market capitalization
- Hepion Pharmaceuticals Debt
- Hepion Pharmaceuticals Liabilities
- Hepion Pharmaceuticals Equity
- Hepion Pharmaceuticals AAQS
- Hepion Pharmaceuticals Employees
- Hepion Pharmaceuticals ROE
- Hepion Pharmaceuticals ROA
- Hepion Pharmaceuticals ROCE
